These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation. Chen C; Liu A; Lu Q; Luo L; Li J; Ke J; Liu Y; Feng X Chem Biol Interact; 2022 Feb; 353():109803. PubMed ID: 34998817 [TBL] [Abstract][Full Text] [Related]
3. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease. Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679 [TBL] [Abstract][Full Text] [Related]
4. Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease. Benoy V; Vanden Berghe P; Jarpe M; Van Damme P; Robberecht W; Van Den Bosch L Neurotherapeutics; 2017 Apr; 14(2):417-428. PubMed ID: 27957719 [TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 6 inhibition mitigates renal fibrosis by suppressing TGF-β and EGFR signaling pathways in obstructive nephropathy. Chen X; Yu C; Hou X; Li J; Li T; Qiu A; Liu N; Zhuang S Am J Physiol Renal Physiol; 2020 Dec; 319(6):F1003-F1014. PubMed ID: 33103445 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of HDAC6 attenuates LPS-induced inflammation in macrophages by regulating oxidative stress and suppressing the TLR4-MAPK/NF-κB pathways. Zhang WB; Yang F; Wang Y; Jiao FZ; Zhang HY; Wang LW; Gong ZJ Biomed Pharmacother; 2019 Sep; 117():109166. PubMed ID: 31255993 [TBL] [Abstract][Full Text] [Related]
14. Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability. Jochems J; Boulden J; Lee BG; Blendy JA; Jarpe M; Mazitschek R; Van Duzer JH; Jones S; Berton O Neuropsychopharmacology; 2014 Jan; 39(2):389-400. PubMed ID: 23954848 [TBL] [Abstract][Full Text] [Related]
15. An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease. Yanda MK; Liu Q; Cebotaru L Am J Physiol Renal Physiol; 2017 Oct; 313(4):F997-F1004. PubMed ID: 28747357 [TBL] [Abstract][Full Text] [Related]
16. Protective Effects of ACY-1215 Against Chemotherapy-Related Cognitive Impairment and Brain Damage in Mice. Wang D; Wang B; Liu Y; Dong X; Su Y; Li S Neurochem Res; 2019 Nov; 44(11):2460-2469. PubMed ID: 31571096 [TBL] [Abstract][Full Text] [Related]
17. Cell-specific role of histone deacetylase 6 in chemotherapy-induced mechanical allodynia and loss of intraepidermal nerve fibers. Ma J; Trinh RT; Mahant ID; Peng B; Matthias P; Heijnen CJ; Kavelaars A Pain; 2019 Dec; 160(12):2877-2890. PubMed ID: 31356453 [TBL] [Abstract][Full Text] [Related]
18. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. Zhang L; Liu C; Wu J; Tao JJ; Sui XL; Yao ZG; Xu YF; Huang L; Zhu H; Sheng SL; Qin C J Alzheimers Dis; 2014; 41(4):1193-1205. PubMed ID: 24844691 [TBL] [Abstract][Full Text] [Related]
19. An HDAC6 inhibitor reverses chemotherapy-induced mechanical hypersensitivity via an IL-10 and macrophage dependent pathway. Zhang J; Ma J; Trinh RT; Heijnen CJ; Kavelaars A Brain Behav Immun; 2022 Feb; 100():287-296. PubMed ID: 34915156 [TBL] [Abstract][Full Text] [Related]